Arcus Biosciences (RCUS) Net Income towards Common Stockholders (QoQ) (2017 - 2026)

Arcus Biosciences (RCUS) Net Income towards Common Stockholders (QoQ) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Arcus Biosciences 3.52 Bn 2.70 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -20.75%
Dec 31, 2025 21.48%
Mar 31, 2025 -19.15%
Dec 31, 2024 -2.17%
Sep 30, 2024 1.08%
Jun 30, 2024 -2,225.00%
Mar 31, 2024 95.06%
Dec 31, 2023 -14.08%
Sep 30, 2023 5.33%
Jun 30, 2023 6.25%
Mar 31, 2023 -19.40%
Dec 31, 2022 -3.08%
Sep 30, 2022 2.99%
Jun 30, 2022 1.47%
Mar 31, 2022 -124.33%
Dec 31, 2021 458.50%
Sep 30, 2021 -2.64%
Jun 30, 2021 -4.65%
Mar 31, 2021 -34.29%
Dec 31, 2020 -3,066.90%